Compare IMUX & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | CHMI |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 83.3M |
| IPO Year | N/A | 2013 |
| Metric | IMUX | CHMI |
|---|---|---|
| Price | $0.55 | $2.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $6.00 | $2.75 |
| AVG Volume (30 Days) | ★ 1.5M | 228.8K |
| Earning Date | 02-14-2026 | 11-06-2025 |
| Dividend Yield | N/A | ★ 15.69% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $40,202,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.73 |
| P/E Ratio | ★ N/A | $136.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $2.17 |
| 52 Week High | $1.39 | $3.68 |
| Indicator | IMUX | CHMI |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 47.08 |
| Support Level | $0.51 | $2.66 |
| Resistance Level | $0.60 | $2.78 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 27.67 | 19.26 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.